Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Xilio Therapeutics Inc (NASDAQ: XLO) closed the day trading at $0.71 down -1.09% from the previous closing price of $0.72. In other words, the price has decreased by -$1.09 from its previous closing price. On the day, 0.7 million shares were traded. XLO stock price reached its highest trading level at $0.734 during the session, while it also had its lowest trading level at $0.7103.
Upgrades & Downgrades
In the most recent recommendation for this company, Leerink Partners on August 06, 2025, initiated with a Outperform rating and assigned the stock a target price of $2. On December 21, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $7. On January 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $36.H.C. Wainwright initiated its Buy rating on January 10, 2022, with a $36 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 16 ’25 when Shannon James Samuel bought 45,000 shares for $0.69 per share. The transaction valued at 30,870 led to the insider holds 45,000 shares of the business.
Shannon James Samuel bought 25,000 shares of XLO for $17,215 on Jun 17 ’25. The Director now owns 70,000 shares after completing the transaction at $0.69 per share. On Jun 16 ’25, another insider, Russo Rene, who serves as the PRESIDENT AND CEO of the company, bought 36,289 shares for $0.68 each. As a result, the insider paid 24,680 and bolstered with 281,172 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XLO now has a Market Capitalization of 37290984 and an Enterprise Value of -59210016. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.17. Its current Enterprise Value per Revenue stands at -1.862 whereas that against EBITDA is 1.404.
Stock Price History:
The Beta on a monthly basis for XLO is -0.05, which has changed by -0.26728588 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, XLO has reached a high of $1.70, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is -8.11%, while the 200-Day Moving Average is calculated to be -5.81%.
Shares Statistics:
Over the past 3-months, XLO traded about 623.76K shares per day on average, while over the past 10 days, XLO traded about 617400 shares per day. A total of 51.83M shares are outstanding, with a floating share count of 23.06M. Insiders hold about 56.79% of the company’s shares, while institutions hold 8.08% stake in the company. Shares short for XLO as of 1764288000 were 6675820 with a Short Ratio of 10.70, compared to 1761868800 on 6156308. Therefore, it implies a Short% of Shares Outstanding of 6675820 and a Short% of Float of 18.360001.
Earnings Estimates
At present, 1.0 analysts are actively evaluating the performance of Xilio Therapeutics Inc (XLO) in the stock market.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.14 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.44 and -$0.44 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.18, with 1.0 analysts recommending between -$0.18 and -$0.18.
Revenue Estimates
1 analysts predict $7.96M in revenue for. The current quarter. It ranges from a high estimate of $7.96M to a low estimate of $7.96M. As of. The current estimate, Xilio Therapeutics Inc’s year-ago sales were $1.72MFor the next quarter, 1 analysts are estimating revenue of $6.9M. There is a high estimate of $6.9M for the next quarter, whereas the lowest estimate is $6.9M.
A total of 1 analysts have provided revenue estimates for XLO’s current fiscal year. The highest revenue estimate was $45.65M, while the lowest revenue estimate was $45.65M, resulting in an average revenue estimate of $45.65M. In the same quarter a year ago, actual revenue was $6.34MBased on 1 analysts’ estimates, the company’s revenue will be $81.75M in the next fiscal year. The high estimate is $81.75M and the low estimate is $81.75M.
